Regulatory & Legal

Now the deadliest cancer for Americans under 50, advocates descend on Washington to demand urgent research funding for a growing national health crisis.

New data reveals a slight drop in Tennessee's youth suicide rates, yet the crisis persists as a leading cause of death, sparking urgent calls for action.

Beyond TVs: TCL's record profits are fueled by a strategic pivot to AI, high-end displays, and a booming renewable energy division, reshaping its global identity.

Dr. Lisa G. Roth, a top oncologist and survivor, takes the helm at Hassenfeld, promising a new era of 'whole person' care for young cancer patients.

Crypto payment giant COINPAYMENTS partners with regulated OSL Group, leveraging local infrastructure to bridge digital assets and mainstream commerce in Asia.

Ten scholarly books are shortlisted for the prestigious 2026 Canada Prizes, tackling decolonization, urban crisis, and Canada's path forward.

Winnie-the-Pooh and executives will star in an AI-animated shareholder update, a bold showcase of tech that could reshape the entire animation industry.

New 3-year trial data shows UCB's BIMZELX prevents painful flares in most HS patients, highlighting a critical window for early intervention.

Independent firm FPA is nominated for a top Morningstar award alongside PIMCO and Vanguard, highlighting its rare focus on investor returns over asset size.

Despite citizenship law debates, investor demand for Portugal's Golden Visa remains strong, signaling a strategic shift towards long-term residency.

After a transformative year, PRF Technologies ditches its old model for a bold new strategy in AI-driven solar analytics and advanced ocular healthcare.

Hyundai, Genesis, and Kia secured 16 top safety ratings, including 15 TSP+ awards, showcasing their leadership under the IIHS's toughest criteria yet.

Hyundai earned a top innovation award for its aggressive EV strategy, new IONIQ 9 SUV, and massive U.S. manufacturing investment. Here's how it happened.

New data shows Dizal's ZEGFROVY achieved an 81.3% response rate in a lung cancer subgroup with limited options, signaling a potential new first-line standard.

RenX Enterprises touts massive growth after a reverse split, but a closer look reveals dilution risks, a heavy debt load, and a paid promotional campaign.

A major investment aims to develop biomarkers for TAND, the neuropsychiatric challenges affecting most with TSC, offering new hope for families.

Benefits giant Alight is on the clock to save its NYSE listing after its stock price collapsed. Can a risky reverse stock split fix its deeper issues?

A landmark partnership aims to tap Australia's vast Beetaloo gas reserves for domestic use and LNG export, igniting both economic hopes and fierce opposition.

Neutech Group builds on its education, healthcare, and wellness strategy, but a closer look at its 2025 financials reveals a more complex picture.

A French biopharma's leap in synthetic lipid production de-risks its lead drug, eyes a vast sepsis market, and creates new commercial avenues.